SLS Sellas Life Sciences
- 1.355
- +0.065+5.04%
- 1.340
- -0.015-1.11%
Sellas Life Sciences News
Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and NovoCure (NVCR)
Buy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened Financials
Buy Rating Affirmed for SELLAS Life Sciences Amidst Promising Drug Development and Strategic Financing
Analysts' Top Healthcare Picks: Olema Pharmaceuticals (OLMA), SELLAS Life Sciences Group (SLS)
Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target
SELLAS Life Sciences Gr Analyst Ratings
Financial Stability and Promising Projects Bolster Buy Rating for SELLAS Life Sciences Group
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), SELLAS Life Sciences Group (SLS) and Outset Medical (OM)
Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target
SELLAS Life Sciences Gr Analyst Ratings
Maxim Group Remains a Buy on SELLAS Life Sciences Group (SLS)
SELLAS Life Sciences Gr Analyst Ratings
Alliance Global Partners Maintains Buy on SELLAS Life Sciences Gr, Lowers Price Target to $8
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cardiovascular Systems (CSII) and SELLAS Life Sciences Group (SLS)
Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and Processa Pharmaceuticals (PCSA)
SELLAS Life Sciences Is Maintained at Overweight by Cantor Fitzgerald
SELLAS Life Sciences Price Target Cut to $6.00/Share From $10.00 by Cantor Fitzgerald
SELLAS Life Sciences Gr analyst ratings
Cantor Fitzgerald Maintains Overweight on SELLAS Life Sciences Gr, Lowers Price Target to $6
Cantor Fitzgerald Adjusts Price Target on SELLAS Life Sciences Group to $6 From $10, Keeps Overweight Rating
Analysis
Price Target
No Data
